
    
      This will be a single center, open-labeled, single arm, phase-II pilot study. The treatment
      and the response evaluation phase will last from the time of enrollment up to 21 months
      (evaluation will be carried out every 3 months in the first 9 months and every 6 months from
      Month 9 to Month 21). The maintenance and follow-up phase to assess for progression of
      disease will last from 21 months to 45 months after enrollment (evaluation will be carried
      out every 12 months). The total study duration will be 4 years after the last patient starts
      study medication.
    
  